These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34355370)

  • 1. Quality of life of patients with pulmonary arterial hypertension: a meta-analysis.
    Sarzyńska K; Świątoniowska-Lonc N; Dudek K; Jonas K; Kopeć G; Gajek J; Jankowska-Polańska B
    Eur Rev Med Pharmacol Sci; 2021 Aug; 25(15):4983-4998. PubMed ID: 34355370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
    Kuang HY; Li Q; Du HA; Chen M; Yin YH
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):181-191. PubMed ID: 32918210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis.
    Fu W; He W; Li Y; Chen Y; Liang J; Lei H; Fu L; Chen Y; Ren N; Jiang Q; Shen Y; Ma R; Wang T; Wang X; Zhang N; Xiao D; Liu C
    Drug Deliv; 2021 Dec; 28(1):1007-1019. PubMed ID: 34060401
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.
    Han X; Zhang Y; Dong L; Fang L; Chai Y; Niu M; Yu Y; Liu L; Yang X; Qu S; Li S
    Respir Care; 2017 Apr; 62(4):489-496. PubMed ID: 28119496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of iloprost and bosentan in pulmonary arterial hypertension.
    Saleh JA
    Niger J Med; 2008; 17(1):13-9. PubMed ID: 18390125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
    Petrovič M; Locatelli I
    Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
    [No Abstract]   [Full Text] [Related]  

  • 8. Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life.
    Strange G; Keogh AM; Williams TJ; Wlodarczyk J; McNeil KD; Gabbay E
    Respirology; 2008 Sep; 13(5):674-82. PubMed ID: 18713089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
    Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
    Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP).
    Stollfuss B; Richter M; Drömann D; Klose H; Schwaiblmair M; Gruenig E; Ewert R; Kirchner MC; Kleinjung F; Irrgang V; Mueller C
    J Med Internet Res; 2021 Oct; 23(10):e25163. PubMed ID: 34623313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
    McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
    Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of musculoskeletal pain and its impact on quality of life and functional exercise capacity in patients with pulmonary arterial hypertension.
    Zeren M; Demir R; Sinan UY; Mustafaoglu R; Yildiz A; Kucukoglu MS
    Respir Med; 2022 Mar; 193():106759. PubMed ID: 35134632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension.
    He B; Zhang F; Li X; Tang C; Lin G; Du J; Jin H
    Circ J; 2010 Jul; 74(7):1458-64. PubMed ID: 20519876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension.
    Chen H; Rosenzweig EB; Gotzkowsky SK; Arneson C; Nelsen AC; Bourge RC
    Health Qual Life Outcomes; 2013 Mar; 11():31. PubMed ID: 23496856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
    Li Q; Kuang HY; Wu YH; Lu TW; Yi QJ
    Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia].
    Shmalts AA; Gorbachevsky SV
    Ter Arkh; 2020 Dec; 92(12):80-85. PubMed ID: 33720578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of psychological factors on the health-related quality of life of patients treated for pulmonary arterial hypertension.
    Halimi L; Marin G; Molinari N; Gamez AS; Boissin C; Suehs CM; Vachier I; Bourdin A
    J Psychosom Res; 2018 Feb; 105():45-51. PubMed ID: 29332633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G; Mehta S
    Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of pulmonary arterial hypertension associated to systemic sclerosis].
    Hachulla E
    Rev Med Interne; 2004 Mar; 25(3):195-200. PubMed ID: 15049280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.